Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

Dan Huang, Yan Ding, Ming Zhou, Brian I. Rini, David Petillo, Chao Nan Qian, Richard Kahnoski, P. Andrew Futreal, Kyle A. Furge, Bin Tean Teh

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients develop sunitinib resistance and progressive disease after about 1 year of treatment. In this study, we evaluated the mechanisms of resistance to sunitinib to identify the potential tactics to overcome it. Xenograft models were generated that mimicked clinical resistance to sunitinib. Higher microvessel density was found in sunitinib-resistant tumors, indicating that an escape from antiangiogenesis occurred. Notably, escape coincided with increased secretion of interleukin-8 (IL-8) from tumors into the plasma, and coadministration of an IL-8 neutralizing antibody resensitized tumors to sunitinib treatment. In patients who were refractory to sunitinib treatment, IL-8 expression was elevated in ccRCC tumors, supporting the concept that IL-8 levels might predict clinical response to sunitinib. Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy.

Original languageEnglish (US)
Pages (from-to)1063-1071
Number of pages9
JournalCancer Research
Volume70
Issue number3
DOIs
StatePublished - Feb 1 2010

Fingerprint

Angiogenesis Inhibitors
Interleukin-8
Renal Cell Carcinoma
Neoplasms
sunitinib
Tumor Escape
Therapeutics
Disease Resistance
Kidney Neoplasms
Microvessels
Neutralizing Antibodies
Heterografts
Phosphotransferases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C. N., ... Teh, B. T. (2010). Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Research, 70(3), 1063-1071. https://doi.org/10.1158/0008-5472.CAN-09-3965

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. / Huang, Dan; Ding, Yan; Zhou, Ming; Rini, Brian I.; Petillo, David; Qian, Chao Nan; Kahnoski, Richard; Futreal, P. Andrew; Furge, Kyle A.; Teh, Bin Tean.

In: Cancer Research, Vol. 70, No. 3, 01.02.2010, p. 1063-1071.

Research output: Contribution to journalArticle

Huang, D, Ding, Y, Zhou, M, Rini, BI, Petillo, D, Qian, CN, Kahnoski, R, Futreal, PA, Furge, KA & Teh, BT 2010, 'Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma', Cancer Research, vol. 70, no. 3, pp. 1063-1071. https://doi.org/10.1158/0008-5472.CAN-09-3965
Huang, Dan ; Ding, Yan ; Zhou, Ming ; Rini, Brian I. ; Petillo, David ; Qian, Chao Nan ; Kahnoski, Richard ; Futreal, P. Andrew ; Furge, Kyle A. ; Teh, Bin Tean. / Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. In: Cancer Research. 2010 ; Vol. 70, No. 3. pp. 1063-1071.
@article{714557bf32fe428ca4cb22975218736b,
title = "Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma",
abstract = "The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients develop sunitinib resistance and progressive disease after about 1 year of treatment. In this study, we evaluated the mechanisms of resistance to sunitinib to identify the potential tactics to overcome it. Xenograft models were generated that mimicked clinical resistance to sunitinib. Higher microvessel density was found in sunitinib-resistant tumors, indicating that an escape from antiangiogenesis occurred. Notably, escape coincided with increased secretion of interleukin-8 (IL-8) from tumors into the plasma, and coadministration of an IL-8 neutralizing antibody resensitized tumors to sunitinib treatment. In patients who were refractory to sunitinib treatment, IL-8 expression was elevated in ccRCC tumors, supporting the concept that IL-8 levels might predict clinical response to sunitinib. Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy.",
author = "Dan Huang and Yan Ding and Ming Zhou and Rini, {Brian I.} and David Petillo and Qian, {Chao Nan} and Richard Kahnoski and Futreal, {P. Andrew} and Furge, {Kyle A.} and Teh, {Bin Tean}",
year = "2010",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-09-3965",
language = "English (US)",
volume = "70",
pages = "1063--1071",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

AU - Huang, Dan

AU - Ding, Yan

AU - Zhou, Ming

AU - Rini, Brian I.

AU - Petillo, David

AU - Qian, Chao Nan

AU - Kahnoski, Richard

AU - Futreal, P. Andrew

AU - Furge, Kyle A.

AU - Teh, Bin Tean

PY - 2010/2/1

Y1 - 2010/2/1

N2 - The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients develop sunitinib resistance and progressive disease after about 1 year of treatment. In this study, we evaluated the mechanisms of resistance to sunitinib to identify the potential tactics to overcome it. Xenograft models were generated that mimicked clinical resistance to sunitinib. Higher microvessel density was found in sunitinib-resistant tumors, indicating that an escape from antiangiogenesis occurred. Notably, escape coincided with increased secretion of interleukin-8 (IL-8) from tumors into the plasma, and coadministration of an IL-8 neutralizing antibody resensitized tumors to sunitinib treatment. In patients who were refractory to sunitinib treatment, IL-8 expression was elevated in ccRCC tumors, supporting the concept that IL-8 levels might predict clinical response to sunitinib. Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy.

AB - The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients develop sunitinib resistance and progressive disease after about 1 year of treatment. In this study, we evaluated the mechanisms of resistance to sunitinib to identify the potential tactics to overcome it. Xenograft models were generated that mimicked clinical resistance to sunitinib. Higher microvessel density was found in sunitinib-resistant tumors, indicating that an escape from antiangiogenesis occurred. Notably, escape coincided with increased secretion of interleukin-8 (IL-8) from tumors into the plasma, and coadministration of an IL-8 neutralizing antibody resensitized tumors to sunitinib treatment. In patients who were refractory to sunitinib treatment, IL-8 expression was elevated in ccRCC tumors, supporting the concept that IL-8 levels might predict clinical response to sunitinib. Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=76249133170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249133170&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3965

DO - 10.1158/0008-5472.CAN-09-3965

M3 - Article

C2 - 20103651

AN - SCOPUS:76249133170

VL - 70

SP - 1063

EP - 1071

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -